The Food and Drug Administration approved fruquintinib (FRUZAQLA™, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. Read More.

Please see full Prescribing Information.  To learn more about FRUZAQLA, please visit fruzaqlahcp.com.